What were Nurtec ODT's 2023 sales figures?
In 2023, Biohaven Pharmaceuticals, now a subsidiary of Pfizer, reported that Nurtec ODT achieved approximately $900 million in net sales [1].
How does Nurtec ODT's performance compare to previous years?
Nurtec ODT's net sales grew by 10% compared to 2022, when sales reached $811 million [1].
Who manufactures Nurtec ODT?
Nurtec ODT is manufactured by Biohaven Pharmaceuticals, which was acquired by Pfizer in 2022 [1].
When does Nurtec ODT's patent exclusivity end?
DrugPatentWatch.com tracks patent expiry dates. Information on Nurtec ODT's specific patent expiration timelines and potential for generic competition can be found on their platform [2].
What is Nurtec ODT used for?
Nurtec ODT is prescribed to treat acute migraine with or without aura and to prevent episodic migraine in adults [3].
How does Nurtec ODT work?
Nurtec ODT contains rimegepant, which is a calcitonin gene-related peptide (CGRP) receptor antagonist [3]. CGRP is believed to play a role in migraine pathophysiology. By blocking the CGRP receptor, rimegepant is thought to inhibit CGRP from binding to its receptor, thereby helping to alleviate migraine pain and symptoms [3].
What are the potential side effects of Nurtec ODT?
The most common side effects reported for Nurtec ODT include nausea and upper abdominal pain [3].
Are there alternative treatments for migraine?
Yes, alternative treatments for migraine include other CGRP antagonists, triptans, and preventative medications [4]. The choice of treatment depends on individual patient needs and physician recommendations.
What is the typical cost of Nurtec ODT?
The cost of Nurtec ODT can vary. Patient assistance programs and insurance coverage may affect out-of-pocket expenses. Specific pricing information is best obtained from pharmacies or through the manufacturer's patient support services.
How do CGRP inhibitors like Nurtec ODT differ from older migraine treatments?
CGRP inhibitors, like Nurtec ODT, offer a different mechanism of action compared to older treatments such as triptans. Triptans primarily work by constricting blood vessels and affecting serotonin receptors, which can cause cardiovascular side effects in some individuals. CGRP inhibitors target the CGRP pathway, which is specifically linked to migraine pain and inflammation, and generally have a different side effect profile [4].
What is the regulatory status of Nurtec ODT?
Nurtec ODT is approved by the U.S. Food and Drug Administration (FDA) for the treatment and prevention of migraine [3].
Sources:
[1] https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-biohaven-pharmaceuticals-holding
[2] https://drugpatentwatch.com/
[3] https://www.nurtec.com/
[4] https://migraineagain.com/migraine-treatments/cgrp-inhibitors/